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Abstract
Object: This study aimed to investigate the effects of Passiflora in-
carnata L. on anxiety in humans. 
Method: The individuals were randomly assigned to one of the fo-
llowing groups: Placebo or experimental, n =30, single dose, as well 
as Placebo or Experimental, n =15, multiple dose.  The experimental 
human anxiety was induced by simulated public speaking test in the 
following phases: Basal (B), stressful (A), speech 1 (S1), speech 2 (S2) 
and Final (F). We evaluated the Systolic Blood Pressure (SBP), and 
Diastolic (DBP), Heart Rate (HR), Electrical Conductance of Skin and 
extremities temperature (ET) and filled The state-trait anxiety inventory 
(STAI S e T). 
Results: During the single dose, the HR was reduced at the end of 
the speech (86±2.0 to 74±3.0 bpm) the experimental group com-
pared to the placebo group (p<0.05); the STAI-S did not change. In 
the delineation of multiple doses, SBP was reduced, in mmHg, in the 
experimental group compared to the placebo group during all pha-
ses. Experimental: 106±1.0 (B), 111±1.0 (A), 121±2.0 (S1), 115±3 (S2), 
104±2.0 (F) e Placebo: 121±3.0; 127±3.0; 130±3.0; 130±4.5; 117±3.0 
(p<0.05). 
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Introduction
Anxiety disorders reach over 25% prevalence, inclu-
ding the fear of public speaking [1]. Anxiety compri-
ses emotional and behavioral factors through fear 
manifestation, insecurity, apprehensive anticipa-
tion, catastrophic thinking, increase in wakefulness 
or alert period and physiological, as activation of 
the hypothalamic-pituitary-adrenal (HPA) axis, lea-
ding neurovegetative symptoms such as insomnia, 
tachycardia, pallor, increased perspiration, muscle 
tension, trembling, dizziness, intestinal disorders, 
among others [2]. 
The impact of anxiety on the individuals's health 
covers changes in blood pressure, heart rate and 
an increased risk of cardiovascular diseases such as 
coronary heart disease (risk tripled) and cerebrovas-
cular [3]. 
Therefore, researchers have invested in as natural 
forms taken to treat or ameliorate the symptoms 
of anxiety, such as the use of herbs. Plants that are 
most studied with anxiolytic potential are Kawa, the 
St. John's Wort and Passiflora spp. [4-7]. The Pas-
siflora extract has been used in many researches, 
presenting in their chemical constitution polyphe-
nols, polyunsaturated fatty acids, fiber and other 
substances, such as passiflorin, one indole alkaloid, 
being the last one associated with anxiolytic effects 
[3]. 
The effects of Passiflora incarnata L on anxiety 
was previously assessed in animals [8, 4] and in hu-
mans [9-10] with satisfactory results [7]. Epidemio-
logical studies have shown that the fear of public 
speaking is one of the biggest phobias that affect 
people, being highly prevalent among students [11]. 
The study proposal was to evaluate symptoms of 
anxiety of public speaking, under a single dose and 
multiple doses through the simulated public spea-
king (SPS) test through the intervention with the 
encapsulated dry extract of the whole plant Passi-
flora incarnata L.
Materials and Methods
Subjects A study population consisted of university 
students, adults, healthy, between 24 and 31 years, 
of both sexes, were excluded individuals who had 
any somatic or mental disorder diagnosed; pregnant 
women; individuals with chronic use of drugs.
The study, described as experimental (trial), ran-
domized, double-blind, placebo-controlled, was 
approved by the Health Sciences Centre Research 
Ethics Committee of the Federal University of Paraí-
ba (Protocol number 070/14) .All participants were 
informed about the specifications of the study and 
signed a Informed Consent Agreement which was 
drafted as the guidelines for research involving 
human beings (Resolution 466/12 of the national 
health council/ Ministry of Health).
Sample A sample was constituted by 90 indivi-
duals recruited by filling out the form for partici-
pation in the survey, sent via social network (Face-
book) and emails. Of the 110 invitations sent, only 
20 refused to participate or were withdrawn from 
the study due the exclusion criteria.
Of the total, the subjects were randomly assigned 
to one of the following groups: Placebo or Experi-
mental, n = 30, single dose and placebo or experi-
mental, n = 15, multiple doses, resulting in all four 
Conclusions: It is suggested that supplementation using Passiflora 
incarnata L. Capsules (500 mg) decreased cardiovascular signals both 
in single and in multiple doses, associated with the stress of public 
speaking.
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Anxiety; Passiflora Incarnata L; 
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groups. The sampling was based on previous stu-
dies using similar sample size and obtained positive 
results [14, 10].
Induction of experimental human anxiety The ex-
perimental human anxiety was induced by simulated 
public speaking test (SPS) [12, 13].This model causes 
anxiety for placing the volunteer to speak in front of 
a video camera . The induced anxiety and the effect 
produced by the substances used in the experiment 
can then be assessed using psychometric scales and 
physiological measurements [15, 16]. The Table 1 
shows the result of the experimental session. 
Measurements The physiological measures inclu-
de systolic blood pressure, diastolic blood pressure, 
heart rate, extremities temperature, electrical Con-
ductance of skin. Together, these measures allow 
to investigate the occurrence of possible hemody-
namic, thermal and perspiration of the extremities 
changes. The measurement of physiological para-
meters (ECS and ET) was performed using a suita-
ble device, the physiograph I-330-C2 Plus Clinical 
System®. The SBP, DBP and HR were measured by 
a digital sphygmomanometer (Omrom, Brazil) atta-
ched to the voluntary’s left wrist.
The psychological measurements were perfor-
med through the application of do state-trait anxie-
ty inventory (STAI), produced by Spielberg, Gorsuch 
and Lushene (1970) [17], translated and validated 
to Portuguese by Biaggio and Natalício (1979) [18]. 
STAI is a test compound by two self-assessment 
questionnaires trait anxiety inventory and the state 
anxiety inventory.
Supplementation protocol The dry extract of Pas-
siflora incarnata L., arising out of the whole plant, 
was standardized to a content of 0.29% of vitexin, 
purchased from a druggist in the city of João Pes-
soa, PB. The extract and the placebo capsules com-
posed of 500 mg of identical appearance. Placebo 
capsules contained inactive substance (starch).
After baseline measurements were provided to 
each participant of the single administration groups 
one capsule. They waited 1 hour and a half and 
continued in the other experimental steps, while 
those from groups of multiple doses, after the ba-
seline measurements, received 6 capsules properly 
labeled with all necessary information for 6 days 
ingestion. The subjects were instructed to eat them 
with water as a way to standardize the ingestion 
and maintain their lifestyle during the trial period. 
Regarding the timing of ingestion, the moment of 
ingestion of a single dose groups depended on the 
appointment with the participant, while the multiple 
doses groups were instructed to take after dinner. 
They had to take one capsule per day for 6 days. 
The experiments were performed in the morning 
shift.
A specific questionnaire on the appearance and 
the possible side effects characteristics was applied 
after the end of the experiment, being answered by 
the volunteer himself.
Statistical Analysis Statistical analysis was per-
formed using the statistical program GraphPad 
Prism (Version 6.00, GraphPad Software Inc., San 
Table 1.  Sequence of the experimental session.
Session 
(min)
Phase Procedures
-0:30 Adaptation to the laboratory; 
instructions on interventions and 
measurements
-0:15 Basal (B) STAI-T, STAI-E, SBP, DBP, HR, ECS, ET
0 Ingestion of the capsule: placebo or 
experimental
+1:30 Stressful (A) Instructions about SPS
+1:32 Discourse preparation, SBP, DBP, HR, 
ECS, ET, STAI-E
+1:34 Speech 
1(S1)
Beginning of the speech
+1:36 Interruption in order to fill the STAI-E
+1:38 Speech 2 
(S2)
Continuation of speech; DBP, SBP, 
HR, ECS, ET, STAI-E
+1:40 End of speech
+1:55 Final (F) DBP, SBP, HR, ECS, ET, STAI-E
STAI-T: Trait anxiety inventory; STAI-E: State anxiety inventory; 
SBP: Systolic blood pressure; DBP: Diastolic blood pressure; 
HR: Heart rate; ET: extremities temperature; ECS: Electrical 
Conductance of Skin; SPS: Simulated Public Speaking
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Diego, CA, USA). Normality was evaluated by the 
test D´Agostino-Pearson omnibus. In the design of 
single administration, the physiological parameters 
SBP, DBP, HR, ET, ECS and psychological by STAI-T 
e E were compared between the placebo and expe-
rimental groups by the test t (Student) or nonpara-
metric corresponding (U Mann-Whitney). To check 
the side effects it was used the Fisher's exact test. 
Data were analyzed with a significance level of 5% 
(P <0.05).
Results
Single Administration 
The analysis of psychological and physiological pa-
rameters (Table 2) shows that the population had 
a uniformity during the initial evaluation, with no 
statistical difference between the groups (p> 0.05), 
except for the SBP.
Comparing the SBP groups showed an increa-
se in the experimental group (118 ± 2.0 mmHg) 
compared to the placebo group (110 ± 2.0 mmHg) 
at baseline phase (p <0.05). DBP increased in the 
experimental group (74 ± 1.7 mm Hg) compared 
to the placebo group (62 ± 1.6 mmHg) at phase 
S1, a statistical variation (p <0.05). HR increased in 
stressful phase (78 ± 3.0 bpm) in the experimental 
group compared to the placebo group (68 ± 3.0 
bpm) (p <0.05), however declined throughout the 
speech (92 ± 3.0 to 80 ± 2.0 bpm and 86 ± 2.0 
to 74 ± 3.0 bpm, S1 and S2, respectively) in the 
experimental group compared to the placebo group 
(p <0.05) (Figure 1). Considering all stages of SPS 
analysis between the groups showed no statistical 
differences of the ECS and ET (p> 0.05). 
The STAI-T experiment was evaluated only in the 
initial moment in each of the experimental groups, 
the analysis of the data shows that the same par-
ticipants began the tests with moderate levels of 
anxiety (33-49 points) [17] (Table 2). The compari-
sons between the groups showed no statistical di-
fferences (p> 0.05) compared to the scores of the 
STAI-E.
Table 2.  Sample characterization of the groups at 
baseline moment, during the single admi-
nistration.
Variables Placebo Experimental P
Subject 30 30 -
Male 15 15 -
Female 15 15 -
Age1(years) 24.9±3.4 24.9±3.4 0.90
STAI-T2 (points) 46 (43-49) 46 (42-49) 0.80
STAI-E2 (points) 42 (40-45) 43 (39-47) 0.90
SBP3 (mmHg) 110±2.0 118±2.0 0.02*
DBP3 (mmHg) 67±1.0 67±1.0 0.65
HR3 (BPM) 80±2.0 74±2.0 0.09
ET3 (°C) 30.15±0.5 30.13±0.5 0.80
ECS3 (µS) 4±0.5 3.8±0.3 0.40
1:Mean ± standard deviation. 2: Median (percentile 25 e 75). 
3: Mean ± standard error mean. STAI-T: Trait anxiety inventory; 
STAI-E: State anxiety inventory; SBP: Systolic blood pressure; 
DBP: Diastolic blood pressure; HR: Heart rate; ET: extremities 
temperature; ECS: Electrical Conductance of Skin, 
mmHg: millimeters of mercury, bpm beats per minute. °C: degree 
Celsius. µS: microsiemens. *: Significant compared to placebo 
(p<0.05). Estatistic test: unpaired t test.
Figure 1:  Passiflora incarnata L. effect on the 
Heart rate of groups submitted to Si-
mulated Public Speaking test.
*: Significant compared to the placebo group (p<0.05). 
Values are presented as mean ± standard error. Estatistic test: unpaired t 
test. B (Basal); A (Stressful); S1 (Speach 1); S2 (Speach 2) e F (Final).
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Multiple doses
The analysis of psychological and physiological 
parameters (Table 3) shows that the population 
had a uniformity during the initial evaluation, with 
no statistical difference between the groups. The 
exception was the DBP that showed a reduction 
in the experimental group (p <0.05) compared to 
placebo.
The comparison between SBP groups was redu-
ced, in mmHg, in the experimental group compared 
to the placebo group during all phases. Experimen-
tal: 106 ± 1.0 (B) 111 ± 1.0 (A) 121 ± 2.0 (S1) 115 
± 3 (S2) 104 ± 2.0 (F) and Placebo: 121 ± 3.0; 127 
± 3.0; 130 ± 3.0; 130 ± 4.5; 117 ± 3.0 (p <0.05) 
(Figure 2). There were no significant changes as the 
DBP in any of the five phases evaluated (p> 0.05). 
HR increased in stressful phase (86 ± 3.0 bpm) in 
the experimental group compared to the placebo 
group (77 ± 4.0 bpm), as well as during the speech 
1 (91 ± 3.0 bpm) in the experimental group compa-
red to the placebo group (3.0 ± 81 bpm) (p <0.05). 
Considering all stages of SPS the analysis between 
the groups showed no significant differences of the 
ECS and ET (p> 0.05). (Figure 2)
The STAI-T was evaluated only in the initial 
moment in each of the experimental groups, the 
analysis of the data shows that the same parti-
cipants began the test with mild anxiety levels 
(40-60 points) [17]. There was no difference bet-
ween groups (p> 0.05). There was an increase (p 
<0.05) of the STAI-E scores in the experimental 
group in stressful phase (44 (41-46)) compared 
to the placebo group (41 (38-44 points)). This 
study showed no statistical difference between 
the groups in the side effects (p> 0.05) in any of 
the designs.
Discussion
Studies conducted investigating the Passiflora spp. 
effects on humans about anxiety are scarce, espe-
cially using SPS test, making it unprecedented in 
this respect.
The SPS test shows to be valid for the assessment 
of anxiety in healthy volunteers independent of the 
individual's anxiety-trait, unlike other methods, such 
Table 3.  Characteristics of the sample at baseline 
moment, during repeated doses.
Variables Placebo Experimental P
Variables Placebo Experimental P
Subject 15 15 -
Age1(years) 24.7±3.5 26.4±3.0 0.16
STAI-T2 (points) 44 (42-47) 46 (43-48) 0.40
STAI-E2 (points) 42 (38-45) 45 (42-48) 0.07
SBP3 (mmHg) 121±3.0 106±1.0 0.0001*
DBP3 (mmHg) 66±3.0 67±1.0 0.70
HR3 (bpm) 70±4.0 79±3.0 0.08
ET3 (°C) 30.8±0.5 31±0.5 0.70
ECS3 (µS) 3.5±0.5 3±0.3 0.40
1:Mean ± standard deviation. 2: Median (percentile 25 e 75). 
3: Mean ± standard error mean. STAI-T: Trait anxiety inventory; 
STAI-E: State anxiety inventory; SBP: Systolic blood pressure; 
DBP: Diastolic blood pressure; HR: Heart rate; ET: extremities 
temperature; ECS: Electrical Conductance of Skin, 
mmHg: millimeters of mercury, bpm beats per minute. °C: degree 
Celsius. µS: microsiemens. *: Significant compared to placebo 
(p<0.05). Estatistic test: unpaired t test.
Figure 2:  Passiflora incarnata L. effect on the sys-
tolic blood pressure of groups submit-
ted to Simulated Public Speaking test.
*: Significant compared to the placebo group (p<0.05). 
Values are presented as mean ± standard error. Estatistic test: unpaired t 
test. B (Basal); A (Stressful); S1 (Speach 1); S2 (Speach 2) e F (Final).
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as the Stroop Color-Word Test, which is prerequisite 
high levels of trait anxiety [15]. In the present stu-
dy there were no significant differences in anxiety-
Trait Anxiety nor the State when the groups were 
compared. A likely explanation is the fact that of 
the little sensitivity by the scale effects of anxiolytic 
drugs [16].
In this study, using the Passiflora incarnata L., 
there was a reduction in heart rate (HR) during the 
whole speech in the experimental group with single 
administration, but not in multiple doses. In pre-
vious research with human beings, of cannabidiol 
(600mg) (single dose) did not alter the FC [19].
Preclinical study, acute and chronic, previously 
performed in spontaneously hypertensive rats (SHR) 
demonstrated satisfactory results in CF after the 
shell of the fruit of Passiflora edulis administration 
differing from the present study that used the dry 
extract of the whole plant from another species in 
healthy subjects. The effects were coming from the 
edulílico acid and anthocyanin fraction [20]. 
Regarding systolic blood pressure (SBP) there was 
a reduction in all phases of speech in experimental 
group compared to the placebo group in the de-
sign of repeated doses. The antihypertensive pro-
perties of passion fruit were previously reported in 
preclinical studies performed in SHR rats. A study 
supplemented the rats with the passion fruit flesh 
for five days to give hypotensive effect, and the 
effect attributed to the increased antioxidant ac-
tivity in animals, since the pulp of the fruit is rich 
in phenolic compounds, ascorbic acid, carotenoids 
and flavonoids [21, 22]. 
In humans, the use of natural products such as 
Erytrina mulungu (500 mg) acute form Matricaria 
recutita (chamomile; 220 mg) for 8 weeks and ofici-
nallis L. Melissa (lemon balm, 600 mg) for two wee-
ks demonstrated anxiolytic effects by Corah scales 
modified, Hamilton Anxiety Scale and the Free Ra-
ting Scale for Anxiety, respectively [23, 24, 25].
 The fermented ginseng was used in a clinical 
study of character and preclinical and demonstrated 
anxiolytic effect in the test light-dark transition in 
animals and Trait Anxiety Inventory-State, reducing 
the anxiety levels in humans. This study applied 
the STAI before and after within the same group 
evaluated (placebo or experimental). RNAm gene 
expression of enzymes related to the production 
of GABA in the hippocampus increased, although 
salivary markers such as cortisol and urinary such as 
8-hidroxideoxiganosina stress did not change [26].
The exact mechanism of action of Passiflora spp. 
anxiety is unknown, but inhibition of monoami-
ne oxidase (MAO) and activating receptors of the 
gamma-aminobutyric acid (GABA) may be involved. 
GABA is the major inhibitory neurotransmitter and 
orchestrates neuronal excitability. During stressful ti-
mes it acts in the discontinuance of neuronal circuits. 
The low GABA levels are correlated with anxiety. In 
addition, GABA has hypotensive paper and is natu-
rally available plants, herbs [27] and in some foods 
such as gabaron tea and fermented foods such as 
yogurt, milk and cheese, among others [22, 28]. 
GABA has been classified as bioactive compound 
in food and drugs. [29]
Anxiety has been widely studied, but few stu-
dies have evaluated the effects of food. There is an 
association between the consumption of milk with 
full fat such as ice creams and creams with higher 
levels of self-reported anxiety, stress, depression of 
mood and memory reduction [30]. Dietary interven-
tions during pregnancy can reduce the high levels 
of anxiety during this period and promote a better 
reflection for birth and child development [31].
Studies of nutrients such as magnesium combi-
ned with other herbs [32, 33, 34] lysine with argi-
nine [35, 36] have demonstrated anxiolytic effects. 
In addition, n-3 fatty acids (mood regulation), sele-
nium, L-tryptophan amino acid (serotonin produc-
tion), L-phenylalanine and L-tyrosine (production of 
dopamine and noradrenaline), vitamin E, vitamin C 
and vitamin D appear to have functional effects, 
further supporting the role of nutrition in alleviating 
the symptoms of anxiety [27].
InternatIonal archIves of MedIcIne 
sectIon: PsyquIatry & Mental health
ISSN: 1755-7682
2017
Vol. 10 No. 6
doi: 10.3823/2276
© Under License of Creative Commons Attribution 3.0 License 7
The electrical conductance skin (ECS) did not 
change in any of the tests, even though the chan-
ges in the emotional state causes neurovegetative 
changes, for example, increase the activity of the 
sweat glands innervated by cholinergic fibers of 
the Central Nervous System (CNS) [16]. Likewise 
the temperature of the extremities has not chan-
ged. No studies were found that evaluated this 
variable to compare the results of the current 
study.
A study with Disorder Social Anxiety (SAD) pa-
tients with cannabidiol (600 mg) showed no chan-
ge in physiological measures (SBP, DBP, HR and 
ECS) in either group (healthy, with and without 
SAD) and evaluated phases. The Group with SAD 
who received cannabidiol reduced the anxiety le-
vels compared to Healthy Group in the phases of 
anticipation, speech and completion. The placebo 
group SAD reached high scores of anxiety about 
the healthy group during the phase of speech [19]. 
There was no change of these measures in this 
study.
One of the main investigations of the effects 
of P. incarnata on anxiety was a clinical, randomi-
zed and controlled in that evaluated the use of P. 
incarnata extract in the treatment of generalized 
anxiety disorder (n = 32). Similar results were ob-
tained between the groups treated with oxaze-
pam (30 mg/day) and with the product P. incar-
nata extract base (45 drops/day) for four weeks. 
The latter group showed better performance at 
work. The group that received P. incarnata had 
fewer adverse effects than synthetic drugs. The 
evaluator anxiety instrument was the Hamilton 
Anxiety Scale [37].
Conclusions
Supplementation using Passiflora incarnata L. cap-
sules (500 mg) decreased cardiovascular signs, both 
in single and multiple doses, associated with the 
stress of public speaking. More research is needed 
to determine the exact mechanisms of action of 
Passiflora incarnata L., and and also its application 
in different anxiety disorders.
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